Randy P. Juhl retired as the Vice Chancellor for Research Conduct and Compliance for the University of Pittsburgh and Distinguished Service Professor of Pharmacy in 2015.
He received an A.A. from Waldorf College in 1968 and a BS, MS and Ph.D. in pharmacy from the University of Iowa in 1972, 1974 and 1976 respectively. His first academic appointment was at Ferris State University where he served as an assistant professor and director of the school's clinical pharmacy programs.
In 1979 he moved to the University of Pittsburgh to serve as chair of the department of pharmacy practice. In 1986 he was named dean of the School of Pharmacy, a position he held for 16 years until 2002. During his tenure as dean, the school converted its entry level practitioner degree program from the Bachelor's level to the PharmD, instituted advanced practice residencies in conjunction with the University of Pittsburgh Medical Center and other partners, developed an innovative clinical scientist Ph.D. program and increased its endowment more than tenfold. The school also attained a top ten ranking among schools and colleges of pharmacy as measured by grant support from the NIH.
In July of 2002 Dr. Juhl left the deanship to accept the invitation from Chancellor Mark Nordenberg to join the University's senior leadership as Vice Chancellor for Research Conduct and Compliance. His responsibilities as Vice Chancellor included the administrative oversight of the University's Institutional Review Board (IRB), the Institutional Animal Care and Use Committee (IACUC), the Radiation Safety Program, the Recombinant DNA Office and components of the University's conflict of interest reporting and monitoring functions.
Dr. Juhl's research included the effects of disease states and other conditions on the pharmacokinetics and pharmacodynamics of drugs. He has authored or co-authored over 70 manuscripts, abstracts and books on these and related topics.
Dr. Juhl served as President of the Academy of Pharmaceutical Research and Science in the American Pharmaceutical Association in 1992 - 1993. In 1992, he was asked to chair the newly created FDA advisory committee on non-prescription drugs. Dr. Juhl served as this committee's chair from 1992 to 1996. The committee is responsible for advising the FDA on a range of issues related to non-prescription drugs, including the Rx-to-OTC switch process. In 1998, Dr. Juhl was appointed chairman of the Pharmacy Compounding Advisory Committee for the FDA. This new advisory committee was created by the FDA Modernization Act of 1997 to serve as a public forum for the resolution of regulatory issues affecting pharmacy compounding.
Dr. Juhl has been honored as a distinguished alumnus of both Waldorf College (1994) and the University of Iowa College of Pharmacy (2000). In 2008 he was appointed as the School's first Distinguished Service Professor.
In 2015 Dr. Juhl was named Dean Emeritus and Distinguished Service Professor of Pharmacy Emeritus
Effects of disease states and other conditions on the pharmacokinetics and pharmacodynamics of drugs.
1. Juhl RP, Blaug SM. Factors Affecting the Release of Medicaments from Hard Gelatin Capsules. J Pharm Sci. 1973; 62:170.
2. Rosazza JP, Juhl RP, Davis PJ. Tryptophol Formation by Zygosaccharomyces Priorianus. Applied Microbiology. 1973; 26:98, 105.
3. Juhl RP, Perry PJ, Norwood GJ, Martin LR. The Family Practitioner-Clinical Pharmacist Group Practice. A Model Clinic. Drug Intell Clin Pharm. 1974; 8:572-575.
4. Juhl RP. OTC Drugs and Clinical Pharmacy. The Use of Community Pharmacies as Teaching Laboratories. Amer J Pharm Ed. 1975; 39:9-12.
5. Clyne K and Juhl RP. Tardive Dyskinesia. Amer J Hosp Pharm. 1976; 33:481-486. (reprinted in the Hosp Pharmacy Forum. 1976; 5:1-13 and J Maine Med Assn. 1976; 67:129-135.
6. Juhl RP, Kronfol Z, Tsuang MT. Lithium Induced Nephrogenic Diabetes Insipidus. Amer J Hosp Pharm. 1976; 33:843-845.
7. Juhl RP, Summers RW, Guillory JK, Blaug SM, Cheng FH, Brown DD. Effect of Sulfasalazine on Digoxin Bioavailability. Clin Pharmacol Ther. 1976; 20:387-394.
8. Brown DD and Juhl RP. Decreased Bioavailability of Digoxin Due to Antacids and Kaopectate. N Engl J Med. 1976; 295:1034-1037.
9. Perry PJ and Juhl RP. Amphetamine Psychosis. Amer J Hosp Pharm. 1977; 34:883-885
10. Juhl RP, Tsuang MT, Perry PJ. Concomitant Administration of Haloperidol and Lithium Carbonate in Acute Mania. Dis Nerv Syst. 1977; 38:675-676.
11. Perry PJ, Wilding DC, Juhl RP. Anticholinergic Psychosis. Amer J Hosp Pharm. 1978; 35:725-727.
12. Brown DD, Juhl RP, Warner SL. Decreased Bioavailbility of Digoxin Due to Hypocholesterolemic Interventions. Circulation. 1978; 58:164-172.
13. Brown DD, Juhl RP, Warner SL. Effects of Hypocholesterolemic Interventions on Digoxin Bioavailability. Drug Metabolism Reviews. 1979; 9:107-117.
14. Juhl RP. Comparison of Kaolin-Pectin and Activated Charcoal for Inhibition of Aspirin Absorption. Amer J Hosp Pharm. 1979; 36:1097-1098.
15. Kerchner J, Colaluca DM, Juhl RP. Effect of Whole Blood on Insulin Adsorption onto Intravenous Infusion Systems. Amer J Hosp Pharm. 1980; 37:1323-1325.
16. Brown DD, Spector R, Juhl RP. Drug Interactions with Digoxin. Drugs. 1980; 20:198-206.
17. Brown DD, Spector R, Juhl RP. Alterations in the Bioavailability of Digoxin. Practical Cardiology. 1981; 7:91-99.
18. Kroboth PD, Brown A, Lyon JA, Kroboth FJ, Juhl RP. Pharmacokinetics of Single Dose Erythromycin in Normal and Alcoholic Liver Disease Subjects. Antimicrobial Agents Chemotherapy. 1982; 21:135-140.
19. Juhl RP, Van Thiel D, Dittert LW, Albert KS, Smith RB. Pharmacokinetics of Ibuprofen and Sulindac in Alcoholic Liver Disease. Clin Pharmacol Ther. 1983; 104-109.
20. Kroboth PD and Juhl RP. Triazolam - New Drug Evaluation. Drug Intell and Clin Pharm. 1983; 17:495-500.
21. Schwinghammer TL, Kroboth FJ, Juhl RP. Extrapyramidal Reaction Secondary to Oral Promethazine: An Evaluation with Plasma Levels. Clinical Pharmacy. 1984; 3:83-85.
22. Schwinghammer TL, Juhl RP, Dittert LW, Melethil SK, Kroboth FJ, Chungi VS. Comparison of the Bioavailability of Oral, Rectal and Intramuscular Promethazine. Biopharm Drug Disposition. 1984; 5:185-194.
23. Juhl RP, Van Thiel DH, Dittert LW, Smith RB. Alprazolam Pharmacokinetics in Alcoholic Liver Disease. J Clin Pharmacol. 1984; 24:113-119.
24. Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP. Pharmacokinetics and Pharmacodynamics of Alprazolam after Oral and IV Administration. Psychopharmacology. 1984; 84:452-456.
25. Kroboth PD, Smith RB, Sorkin MI, Silver MR, Rault R, Garry M, Juhl RP. Triazolam Protein Binding and Correlation with Alpha-1-Acid Glycoprotein. Clin Pharmacol Ther. 1984; 36:379-383.
26. Juhl RP, Daugherty VM, Kroboth PD. Incidence of Next-Day Anterograde Amnesia Caused by Flurazepam Hydrochloride and Triazolam. Clin Pharmacy. 1984; 3:622-625.
27. Stoehr GP, Kroboth PD, Juhl RP, Wender DB, Phillip JP, Smith RB. Effect of Oral Contraceptives on Triazolam, Temazepam, Alprazolam and Lorazepam Kinetics. Clin Pharmacol Ther. 1984; 36:683-690.
28. Stoehr GP, Juhl RP, Veals J, Symchowicz S, Gural R, McDonald RH. The Excretion of Rosaramicin in Breast Milk. J Clin Pharmacol. 1985; 25:89-94.
29. Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP. Effects of End Stage Renal Disease and Aluminum Hydroxide on Temazepam Kinetics. Clin Pharmacol Ther. 1985; 37:453-459.
30. Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP. Effects of End Stage Renal Disease and Aluminum Hydroxide on Triazolam Pharmacokinetics. Br J Clin Pharmacol. 1985; 19:839-842.
31. Kubacka RT, Juhl RP. Attitudes of Patients with Hypertension or Arthritis Toward the Frequency of Medication Administration. Amer J Hosp Pharm. 1985; 42:2499-2501.
32. Kroboth PD, Smith RB, Stoehr GP, Juhl RP. Pharmacodynamic Evaluation of the Benzodiazepine - Oral Contraceptive Interaction. Clin Pharmacol Ther. 1985; 38:525-532.
33. Howrie DL, Felix C, Wollman M, Juhl RP, Blatt J. Metoclopramide as an Antiemetic Agent in Pediatric Oncology Patients. Drug Intell Clin Pharm. 1986; 20:122-124.
34. Juhl RP, Kroboth PD. Conceptual Issues in Designing a Clinical Scientist Program. Amer J Pharm Ed. 1986; 50:483-485 and Drug Intell Clin Pharm. 1987; 21:103-106. Invited paper, published as complete symposium proceedings in the journals of the two symposium sponsors
35. Smith RB, Kroboth PD, Juhl RP. An Academic - Industrial Center for Pharmacodynamic Research. Amer J Pharm Ed. 1986; 50:472-474 and Drug Intell Clin Pharm. 1987; 21:127-129. Invited paper, published as complete symposium proceedings in the journals of the two symposium sponsors
36. Kubacka RT, Antal EJ, Juhl RP. The Paradoxical Effect of Cimetidine and Ranitidine on Glibenclamide Pharmacokinetics and Pharmacodynamics. Br J Clin Pharmacol. 1987; 23:743-751.
37. Howrie DL, Pieniaszek HJ, Fogoros RN, Juhl, RP, Schary WL, Whitney CC, Dittert LW. Disposition of Moracizine (Ethmozine) in Healthy Subjects After Oral Administration of Radiolabelled Drug. European J Clin Pharmacol. 1987; 32:607-610.
38. Kroboth PD, Smith RB, Van Thiel DH, Juhl RP. Nighttime Dosing of Triazolam in Patients with Liver Disease and Normal Subjects: Kinetics and Daytime Effects. J Clin Pharmacol. 1987; 27:555-560.
39. Juhl RP. (ed.) Drug Product Selection in the 90's. American Pharmacy. 1991; NS31:524-531, 587-593, 655-665, 825-831.
40. Juhl RP. Good science or good business? American Pharmacy. NS32(5):80, 1992 May.
41. Lush RM, McAuley JW, Juhl RP, Kroboth PD. Experimental design in clinical research: A student-centered problem-based approach. Am J Pharmaceut Ed 1993; 57:39-43
42. Kubacka RT, Antal EJ, Juhl RP. The Effect of Aspirin and Ibuprofen on Glyburide Pharmacokinetics and Pharmacodynamics of Glyburide in Healthy Subjects. The Annals of Pharmacotherapy 1996; 30:20-26.
43. Juhl RP. An Interpretative Guide to Chairing and FDA Advisory Committee. Food and Drug Law Journal 1997; 52:133-140.
44. Juhl RP, Foster, TS, Jaeger KD, Osterhaus M (editors). APhA Special Report, Evaluating Therapeutic Equivalence: A Pharmacist’s Guide. American Pharmaceutical Association, 1997
45. Juhl RP. FDA Advisory Committees: A Peer’s Review of Peer Review. Regulatory Affairs Focus. 1998; 3:6:6-8
46. Juhl RP. Prescription to Over-the-Counter Switch: A Regulatory Perspective. Clinical Therapeutics 1998; 20;C111-C117.
47. Juhl, RP. Switching Drug Products from Rx to OTC Status: A Benefit to Pharmacy Practice. US Pharmacist 2000; April, 120-128.
48. Juhl, RP. Options for People Who Have Heartburn, in Heartburn: Early Diagnosis and Effective Treatment. Postgraduate Medicine Special Report, 2000; May, 22-24.
49. Juhl, RP. Faculty in the Drug Industry: Deserters or Missionaries? Am J Health-Syst Pharm. 2002; 59:2099-100.
50. Soller RW, Tong T, Koda Kimble MA, Juhl R, Lam YWF, Rice L. Guiding principles for addressing Rx-to-OTC switch in the context of novel conditions of use for nonprescription medicines. SelfCare 2012;3(4):78-83
BOOKS AND BOOK CHAPTER
1. Juhl RP. Community Pharmacy Practice: Study Guides for OTC Drugs and Patient Counseling. First Edition, 1973.
2. Juhl RP and Cremers BJ. Community Pharmacy Practice: Study Guides for OTC Drugs and Patient Counseling. Second Edition, 1975.
3. Clyne DK and Juhl RP. "Tardive Dyskinesia" in Drug Therapy Reviews Volume 1, edited by DJ Greenblatt and RR Miller, 1977.
4. Juhl RP and Stagner WC. Community Pharmacy Practice: Study Guides for OTC Drugs and Patient Counseling, Third Edition, 1978.
5. Reiland TR and Juhl RP. Supplemental Study Guides for OTC Drugs and Patient Counseling, 1979.
6. Smith RB, Kroboth PD, Juhl RP (Editors). Pharmacokinetics and Pharmacodynamics: Research Design and Analysis. 1986.
7. Kroboth, PD, Smith RB, Juhl RP (Editors). Pharmacokinetics and Pharmacodynamics: Current Problems - Potential Solutions. 1988.